Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 79
Filtrar
Mais filtros

Medicinas Complementares
Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Oncol Rep ; 45(5)2021 05.
Artigo em Inglês | MEDLINE | ID: mdl-33846814

RESUMO

More than 70% of patients with epithelial ovarian cancer (EOC), one of the leading cause of gynecological cancer­related deaths worldwide, are diagnosed at an advanced stage of the disease. Currently, the mainstay for treatment of advanced EOC is tumor debulking surgery followed by combined platinum­ and paclitaxel (PTX)­based chemotherapy. However, most patients eventually develop chemoresistance, which remains a major obstacle to successful treatment. Herein, by using clinical specimens and experimentally induced cell models, we found that the expression levels of hsa­miR­105 were significantly decreased in PTX­resistant EOC tissues and cell lines. Follow­up functional experiments demonstrated that repression of hsa­miR­105 conferred resistance to paclitaxel in EOC cells, whereas restoration of hsa­miR­105 expression in situ via intratumoral injection of hsa­miR­105 micrON™ agomir potentiated in vivo sensitivity to PTX and thereafter significantly inhibited tumor growth in a PTX­challenged xenograft model. Mechanistically, hsa­miR­105 exerted its tumor suppressor function by directly inhibiting the zinc and ring finger 2 (ZNRF2) signaling pathway. Importantly, aberrant expression of hsa­miR­105 in both tumor and circulating samples predicted a poor post­chemotherapy prognosis in EOC patients. These findings collectively suggest that hsa­miR­105 may act as a potent tumor suppressor miRNA during the progression of EOC, likely affecting cell proliferation, invasiveness and chemosensitivity to PTX, and functioning at least in part via inhibition of ZNRF2 signaling. The stability and availability and ease in measurement of circulating hsa­miR­105 make it a valuable diagnostic/prognostic biomarker candidate for chemotherapy of EOC.


Assuntos
Biomarcadores Tumorais/metabolismo , Carcinoma Epitelial do Ovário/terapia , Resistencia a Medicamentos Antineoplásicos/genética , MicroRNAs/metabolismo , Neoplasias Ovarianas/terapia , Paclitaxel/farmacologia , Biomarcadores Tumorais/sangue , Carcinoma Epitelial do Ovário/diagnóstico , Carcinoma Epitelial do Ovário/genética , Carcinoma Epitelial do Ovário/mortalidade , Linhagem Celular Tumoral , Proliferação de Células/genética , Quimioterapia Adjuvante , Procedimentos Cirúrgicos de Citorredução , Conjuntos de Dados como Assunto , Regulação para Baixo , Feminino , Seguimentos , Regulação Neoplásica da Expressão Gênica , Humanos , Estimativa de Kaplan-Meier , MicroRNAs/sangue , Pessoa de Meia-Idade , Neoplasias Ovarianas/diagnóstico , Neoplasias Ovarianas/genética , Neoplasias Ovarianas/mortalidade , Ovariectomia , Ovário/patologia , Ovário/cirurgia , Paclitaxel/uso terapêutico , Ubiquitina-Proteína Ligases/genética , Ensaios Antitumorais Modelo de Xenoenxerto
2.
Gynecol Oncol ; 160(2): 619-624, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-33309416

RESUMO

Cancer treatment-induced bone loss is a known side effect of cancer therapy that increases the risk of osteoporosis and bone fracture. Women with gynecologic cancer are at increased risk of bone loss secondary to the combined effect of oophorectomy and adjuvant therapies. Data regarding bone loss in women with gynecologic cancers are overall lacking compared to other cancer populations. Consequently, guidelines for osteoporosis screening in women with cancer are largely based on data generated among non-gynecologic cancer survivors. This article reviews current available data of bone health in women with gynecologic cancer, summarizes best-available guidelines for screening for osteoporosis in women with cancer, and provides guidance for osteoporosis screening in women with gynecologic cancers based on best available evidence.


Assuntos
Densidade Óssea/fisiologia , Sobreviventes de Câncer/estatística & dados numéricos , Neoplasias dos Genitais Femininos/terapia , Programas de Rastreamento/normas , Osteoporose/diagnóstico , Absorciometria de Fóton , Antineoplásicos Hormonais/efeitos adversos , Densidade Óssea/efeitos dos fármacos , Densidade Óssea/efeitos da radiação , Quimioterapia Adjuvante/efeitos adversos , Quimioterapia Adjuvante/métodos , Medicina Baseada em Evidências/normas , Feminino , Neoplasias dos Genitais Femininos/complicações , Neoplasias dos Genitais Femininos/mortalidade , Humanos , Menopausa/efeitos dos fármacos , Menopausa/metabolismo , Menopausa/efeitos da radiação , Osteoporose/epidemiologia , Osteoporose/etiologia , Osteoporose/metabolismo , Ovário/efeitos dos fármacos , Ovário/metabolismo , Ovário/efeitos da radiação , Ovário/cirurgia , Guias de Prática Clínica como Assunto , Radioterapia Adjuvante/efeitos adversos , Fatores de Risco , Salpingo-Ooforectomia/efeitos adversos , Sobrevivência
3.
Mol Cell Endocrinol ; 518: 110969, 2020 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-32781248

RESUMO

The hypothalamus-pituitary-ovary (HPO) axis plays fundamental roles in female neuroendocrinology and reproduction. Pituitary gonadotropins are located in the center of this axis. Previous investigation suggested that miR-7 is closely linked with gonadotropins. However, the interaction between miR-7 and the HPO axis remains unclear. This study aims to determine whether and how miR-7 functions in this axis. A mouse ovariectomy model and mouse primary pituitary cells were used in this study. The results showed that miR-7 is localized to gonadotrophs and somatotrophs. miR-7 can inhibit the expression, synthesis and secretion of gonadotropins, but not growth hormones. Gonadotropin-releasing hormone (GnRH) has inhibitory effects on miR-7, while estrogen enhances miR-7 expression. miR-7 is vital for the pathway by which GnRH and estrogen regulate gonadotropins by targeting v-raf-leukemia viral oncogene 1 (Raf1). Together, these results indicate that miR-7 acts as a potential switch in the feedback loop of the HPO axis by regulating gonadotropins.


Assuntos
Gonadotropinas/metabolismo , Hipotálamo/metabolismo , MicroRNAs/genética , Ovário/metabolismo , Hipófise/citologia , Proteínas Proto-Oncogênicas c-raf/genética , Animais , Células Cultivadas , Estrogênios/metabolismo , Retroalimentação Fisiológica , Feminino , Regulação da Expressão Gênica , Hormônio Liberador de Gonadotropina/metabolismo , Gonadotropinas/genética , Camundongos , Modelos Animais , Ovariectomia , Ovário/cirurgia , Hipófise/metabolismo , Cultura Primária de Células
4.
J Food Sci ; 85(6): 1956-1962, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-32406939

RESUMO

We evaluated the influence of pine bark extract (PBE) on organs, the cytochrome-P450 (CYP) activities in liver and estrogenic effects in normal and ovariectomized (OVX) female mice. The PBE did not affect organ weights and liver-function indexes (activities of alkaline phosphatase, aspartate amino transferase, and alanine amino transferase) at doses; 0.04%, 0.4%, and 2.0% PBE in the diet, in normal and OVX female mice. In the OVX mice, CYP1A1 activity was significantly higher in the 0.4% and 2.0% PBE groups than in the OVX control group, and in the 0.4% and 2.0% PBE groups were significantly higher than in the 0.04% PBE group. CYP1A2 and 3A4 activities were significantly higher in the 2.0% PBE group than in all other groups. The PBE did not affect uterine weight and femoral bone mineral density at all PBE doses. These results showed that the dose of PBE at the recommended human intake, had no toxic and estrogenic effects in normal female and OVX mice, however, it may need attention to use the excess intake of PBE with some drugs in postmenopausal women.


Assuntos
Osteoporose Pós-Menopausa/tratamento farmacológico , Pinus/química , Casca de Planta/química , Extratos Vegetais/administração & dosagem , Animais , Densidade Óssea/efeitos dos fármacos , Citocromo P-450 CYP1A1/genética , Citocromo P-450 CYP1A1/metabolismo , Citocromo P-450 CYP1A2/genética , Citocromo P-450 CYP1A2/metabolismo , Feminino , Fêmur/química , Fêmur/crescimento & desenvolvimento , Humanos , Camundongos , Tamanho do Órgão/efeitos dos fármacos , Osteoporose Pós-Menopausa/genética , Osteoporose Pós-Menopausa/metabolismo , Osteoporose Pós-Menopausa/fisiopatologia , Ovariectomia , Ovário/metabolismo , Ovário/cirurgia , Extratos Vegetais/efeitos adversos
5.
Vet Surg ; 49 Suppl 1: O54-O59, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31225655

RESUMO

OBJECTIVE: To compare pain-related responses in mares receiving topical or injected anesthesia of the ovarian pedicle prior to standing unilateral laparoscopic ovariectomy. STUDY DESIGN: Prospective randomized, blinded, placebo-controlled study. ANIMALS: Fifteen healthy research mares. METHODS: Mares were restrained in stocks and administered sedation. A right or left paralumbar ovariectomy was performed by using a laparoscopic portal and two instrument portals. Mares were divided into two treatment groups, and equal volumes of mepivacaine anesthesia were administered either topically (n = 8) or by injection into the ovarian pedicle (n = 7). Saline controls were simultaneously administered topically (n = 7) or by injection (n = 8), and surgeons were blinded to the treatment group. Ovarian removal was performed with traumatic forceps and a blunt tip vessel sealer and divider. Pain responses were measured by operative visual analog scale (VAS) scoring and perioperative serum cortisol response. Visual analog scale and serum cortisol were compared between groups by using Mann-Whitney testing. Serum cortisol concentrations were evaluated using repeated-measures one-way analysis of variance. RESULTS: Ovaries were removed in all mares by using the described technique without operative complications. Quantity of sedation required to complete the procedure, operative VAS scores, and perioperative cortisol concentrations did not differ between treatment groups. CONCLUSION: Application of topical mepivacaine to the ovary provided intraoperative analgesia similar to injection of the ovarian pedicle when performing unilateral standing laparoscopic ovariectomy in mares. CLINICAL SIGNIFICANCE: Topical anesthesia application to the ovary could provide an alternative to laparoscopic needle use, reducing the risk of inadvertent trauma to the pedicle or other visceral organs during laparoscopic ovariectomy.


Assuntos
Anestesia Local/veterinária , Cavalos/cirurgia , Laparoscopia/veterinária , Mepivacaína/administração & dosagem , Ovariectomia/veterinária , Anestésicos Locais/administração & dosagem , Anestésicos Locais/farmacologia , Animais , Feminino , Laparoscopia/métodos , Mepivacaína/farmacologia , Ovariectomia/métodos , Ovário/cirurgia , Estudos Prospectivos
6.
Rejuvenation Res ; 22(6): 465-477, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30672382

RESUMO

Radix paeoniae alba (RPA) and Veratrum nigrum (VN) L. belong to the 18 incompatible medicaments and have been prohibited for thousands of years in China. Previous studies focused on the chemical constituents that induced the toxicological response of the two agents, but this study offers preliminary insight into the pharmacodynamics and mechanism on estrogenic activity, which is responsible for their incompatibility. We undertook a characterization of the interaction on estrogenic activity of RPA and VN using in vivo models of immature and ovariectomized (OVX) mice and in vitro studies focused on estrogen receptor (ER) pathway for further mechanism. VN disturbed the estrogenic efficacy of RPA in promoting development of uterus and vagina in immature mice, and reversing the atrophy of reproductive tissues in OVX mice by decreasing the increase of serum estrogen level and upregulation of ER expression in reproductive tissues by treatment with RPA. Besides, VN antagonized the estrogenic efficacy of RPA in stimulating the binding with ERα and ERß, increasing ERα/ß-estrogen response element (ERE) luciferase reporter gene expression and promoting MCF-7 cell viability. This study provided evidence that VN antagonized the estrogenic efficacy of RPA by decreasing the up-regulations of estrogen biosynthesis in circulation and ERs in target tissues caused by RPA, and through ER-ERE-dependent pathway.


Assuntos
Estrogênios/metabolismo , Ovário/metabolismo , Paeonia/química , Extratos Vegetais/farmacologia , Receptores de Estrogênio/metabolismo , Veratrum/química , Animais , Feminino , Humanos , Células MCF-7 , Camundongos , Ovariectomia , Ovário/efeitos dos fármacos , Ovário/cirurgia , Útero/efeitos dos fármacos , Útero/metabolismo , Útero/cirurgia , Vagina/efeitos dos fármacos , Vagina/metabolismo , Vagina/cirurgia
7.
Acupunct Med ; 35(3): 208-214, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-27834684

RESUMO

AIM: To observe the effects of electroacupuncture (EA) on uterine morphology and expression of oestrogen receptor (ER) α and ß in ovariectomised (OVX) rats. METHODS: Thirty female Sprague-Dawley rats with regular 4-day oestrus cycles were divided into a sham operation group (Control, n=10) and two OVX groups that remained untreated (OVX group, n=10) or received EA treatment (OVX+EA group, n=10). In the latter group, EA was applied at CV4, CV3, SP6 and bilateral Zigong (30 min per day) for 3 days. The effects of EA on uterine morphology were observed by H&E staining. Quantitative real-time reverse transcription-PCR (qRT-PCR) and Western blotting were used to measure ERα and ERß mRNA and protein expression, respectively. RESULTS: Relative to the (untreated) OVX group, EA treatment significantly increased the uterine wet weight to body weight (UWW/BW) ratio (0.47±0.04 vs 0.31±0.03 g/kg, p=0.04), and myometrial thickness (109.39±10.71 vs 60.81±8.1 µm, p=0.016) of OVX rats. Similarly, the total number of endometrial glands per cross section and endometrial thickness in the OVX +EA group was significantly increased compared to the (untreated) OVX group. EA treatment also increased protein (but not mRNA) expression of both ERα and ERß in the uteri of OVX rats. CONCLUSIONS: This study has demonstrated that EA treatment decreases uterine atrophy in OVX rats. This unique effect of EA on the uterus may be due to upregulation of serum levels of E2 and differential regulation of sex steroid receptors ERα and ERß.


Assuntos
Eletroacupuntura , Ovário/cirurgia , Receptores de Estrogênio/genética , Útero/crescimento & desenvolvimento , Útero/metabolismo , Animais , Feminino , Tamanho do Órgão , Ovariectomia , Ratos , Ratos Sprague-Dawley , Receptores de Estrogênio/metabolismo , Útero/anatomia & histologia
9.
Biorheology ; 53(1): 23-31, 2016 01 07.
Artigo em Inglês | MEDLINE | ID: mdl-26756280

RESUMO

BACKGROUND: Postmenopausal women often develop hemorheological disorders which may affect the systemic blood circulation and present a cardiovascular risk factor. OBJECTIVE: We evaluated effects of secoisolariciresinol (SECO), a phytoestrogen, on hemorheological parameters and lipid peroxidation in a model of the age-related and/or surgical menopause induced by ovariectomy in rats. METHODS: Arterial blood was sampled from sham-operated female rats, ovariectomized rats (OVX), and OVX treated with SECO (OVXSECO) (20 mg/kg/day intragastrically for two weeks). Plasma estrogen concentration and the following hemorheological parameters were measured: RBC aggregation (half-time of aggregation, T1/2; amplitude of aggregation, AMP; aggregation index, AI), RBC deformability (elongation index, EI), whole blood viscosity at the shear rate of 3-300 s-1, plasma viscosity, hematocrit, plasma fibrinogen. Lipid peroxidation was evaluated by measuring conjugated dienes (CD) and thiobarbituric acid reactive substances (TBARS) in plasma. RESULTS: Ovariectomy in rats caused a 60% decrease in plasma estrogen level and triggered the development of macro- and microhemorheological abnormalities. Blood viscosity increased by 12-31%, RBC elongation index reduced by 16-28%, and T1/2 and AI increased by 35% and 29% respectively. The increase in blood viscosity correlated predominantly with reduced RBC deformability. Plasma CD and TBARS were elevated by 47% and 104% respectively. SECO therapy for OVX rats reduced blood viscosity by 9-18% and T1/2 by 32%, and increased EI by 4-17%. SECO therapy disrupted the correlation between blood viscosity and RBC deformability. Lipid peroxidation was significantly inhibited, as shown by the reduction in CD and TBARS plasma concentrations by 89% and 70% respectively. SECO did not affect plasma viscosity, estrogen or fibrinogen levels. CONCLUSIONS: SECO treatment for OVX rats improves blood macro- and microrheological parameters, possibly through antioxidant protection of RBC.


Assuntos
Viscosidade Sanguínea/efeitos dos fármacos , Butileno Glicóis/farmacologia , Agregação Eritrocítica/efeitos dos fármacos , Deformação Eritrocítica/efeitos dos fármacos , Hemorreologia/efeitos dos fármacos , Lignanas/farmacologia , Ovariectomia/efeitos adversos , Fitoestrógenos/farmacologia , Animais , Estradiol/sangue , Feminino , Hematócrito , Peroxidação de Lipídeos/efeitos dos fármacos , Ovário/cirurgia , Ratos , Ratos Wistar
10.
Pediatr Surg Int ; 32(1): 71-3, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26500075

RESUMO

PURPOSE: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been used in adults with ovarian carcinoma proving overall survival benefit in randomized trials, but measured in months. Diffuse peritoneal disease from pediatric type ovarian tumors is rare. We applied CRS and HIPEC to pediatric girls with diffuse peritoneal disease as part of a clinical trial. METHODS: In all patients complete cytoreduction was followed by HIPEC using 100 mg/m2 of cisplatin for 90 min in a closed technique. All received neoadjuvant chemotherapy. Patients with disease outside of the abdominal cavity were excluded. RESULTS: Of 101 pediatric CRS and HIPEC operations, 8 had ovarian primary tumors and multifocal peritoneal disease. There were three yolk sac tumors (germ cell, mixed teratoma), one Sertoli­Leydig, one PNET of the ovary, one choriocarcinoma, one juvenile granulosa cell tumor and one adenocarcinoma. Age ranged 4­18 years. Three of the 8 (37 %) recurred and died. The remaining 63 % are disease free 2­6 years post HIPEC. Overall survival and relapse-free survival in this cohort was 64 and 62 %, respectively [CI 0.64 (0.34, 1); 0.62 (0.37, 1)]. CONCLUSIONS: This is the first report of CRS and HIPEC in pediatric ovarian tumors. HIPEC may be effective in pediatric-type ovarian tumors. More study is needed in a larger cohort.


Assuntos
Procedimentos Cirúrgicos de Citorredução , Hipertermia Induzida , Neoplasias Ovarianas/complicações , Neoplasias Ovarianas/terapia , Doenças Peritoneais/complicações , Adolescente , Antineoplásicos/uso terapêutico , Quimioterapia Adjuvante , Cisplatino/uso terapêutico , Terapia Combinada , Feminino , Humanos , Terapia Neoadjuvante , Ovário/cirurgia , Cavidade Peritoneal , Doenças Peritoneais/terapia , Peritônio , Análise de Sobrevida , Resultado do Tratamento
11.
J Reprod Med ; 60(7-8): 345-53, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26380495

RESUMO

OBJECTIVE: To assess subsequent utilization of fertility treatment in reproductive-age women with cervical cancer (CC) who underwent ovarian transposition (OT) to preserve fertility prior to pelvic radiation. STUDY DESIGN: This is a case series of 216 CC patients seen in a comprehensive cancer center. Sixteen patients underwent OT for fertility preservation prior to pelvic radiation. Patients were assessed for utilization of fertility treatment, follicle-stimulating hormone (FSH) levels as a measure of ovarian reserve, and functional assessment of chronic illness therapy-cervix cancer (FACT-CX) to assess quality of life after OT. RESULTS: Of the patients, 94% of patients [corrected] maintained regular menstrual cycles 3 years after ovarian transposition (OT) [corrected] surgery (15/16). When measured (n = 5), serum FSH was normal at baseline and showed a transient elevation at 3 months following chemoradiation, with a return to normal levels at 6 months (means, 6.33 ± 2.94, 48.44 ± 18.63, and 12.52 ± 8.25 mIU/mL, respectively). Only 1 patient in this series attempted fertility treatment (in vitro fertilization) following OT, and she did not become pregnant. FACT-CX indicated that quality of life did not change significantly over the 6 months' duration following OT and chemoradiation therapy. CONCLUSION: OT preserves menstrual cycle regularity without negatively impacting patients' quality of life. The utility of OT as an effective fertility preservation option is hampered by the low utilization rate of in vitro fertilization and lack of ovarian reserve assessment following OT.


Assuntos
Preservação da Fertilidade/estatística & dados numéricos , Fertilização in vitro/estatística & dados numéricos , Ovário/cirurgia , Neoplasias do Colo do Útero/epidemiologia , Neoplasias do Colo do Útero/radioterapia , Neoplasias do Colo do Útero/cirurgia , Adulto , Feminino , Preservação da Fertilidade/métodos , Humanos , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento , Adulto Jovem
12.
J Acupunct Meridian Stud ; 8(1): 44-7, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25660444

RESUMO

The aim of this study is to investigate paraclinical changes in glycemia, serum cortisol, and adrenocorticotropic hormone (ACTH) due to electroacupuncture analgesia (EAA) in a rabbit undergoing an ovariohysterectomy. Seven clinically healthy New Zealand white rabbits were used in this study. Local and systemic analgesia was represented by EAA. Blood samples were collected at preoperative, operative, and postoperative times. At the operative time, increased cortisolemia does not promote a proportional increase in glycemia even though it is correlated with an increased level of ACTH. EAA follows the stress mechanism, which is coordinated by neuroendocrine activity. EAA in a rabbit ovariohysterectomy underscores the crucial involvement of the hypothalamus-pituitary-adrenal axis with a direct influence on paraclinical changes, including changes in glycemia, cortisol, and ACTH, which are specific for stress changes.


Assuntos
Analgesia por Acupuntura , Eletroacupuntura , Manejo da Dor , Hormônio Adrenocorticotrópico/sangue , Animais , Feminino , Glucose/metabolismo , Humanos , Hidrocortisona/sangue , Ovariectomia , Ovário/cirurgia , Sistema Hipófise-Suprarrenal/metabolismo , Coelhos
13.
Int J Mol Sci ; 15(5): 7827-40, 2014 May 06.
Artigo em Inglês | MEDLINE | ID: mdl-24806341

RESUMO

Ginseng is a popular herb for alleviating menopausal symptoms; however, no conclusive scientific data has shown ginseng as being efficient in such therapies. The present study was designed to evaluate the estrogenic efficacy of ginseng on reproductive target tissues of ovariectomized (OVX) mice. The OVX mice were treated with ginseng at doses of 12.0, 18.0 and 24.0 g/kg per day for four weeks. Ginseng treatments restored the estrus cycle and demonstrated significant estrogenic activity, as indicated by the reversal of the atrophy of the uterus and vagina, upregulation of estrogen receptor (ER) α and ER ß expression at the protein and mRNA level in the reproductive tissues, where ER α upregulation was stronger than that of ER ß. Meanwhile, treatment with ginseng significantly increased adrenal gland weight and serum estradiol and clearly decreased follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in circulation. Notably, the largest changes in these parameters were found at the highest dose of 24.0 g/kg. Moreover, ginseng at 18.0 g/kg resulted in the greatest decrease in weight gain caused by ovariectomy. The data suggest that ginseng estrogenic responses show tissue variation that reflects different affinities of ERs for ginseng components. This study demonstrates that ginseng activity is mediated through estrogenic components and provides further evidence for ginseng treatment of postmenopausal symptoms.


Assuntos
Estrogênios/uso terapêutico , Ovariectomia , Panax , Preparações de Plantas/uso terapêutico , Útero/efeitos dos fármacos , Vagina/efeitos dos fármacos , Animais , Estradiol/sangue , Estrogênios/química , Feminino , Hormônio Luteinizante/sangue , Camundongos , Tamanho do Órgão/efeitos dos fármacos , Ovário/cirurgia , Panax/química , Fitoterapia , Preparações de Plantas/química , Receptores de Estrogênio/análise , Receptores de Estrogênio/genética , Receptores de Estrogênio/metabolismo , Regulação para Cima/efeitos dos fármacos , Útero/patologia , Vagina/patologia
14.
Ann Surg Oncol ; 20(6): 1837-42, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23370670

RESUMO

OBJECTIVE: To appreciate if the ovaries can be preserved in selected young women with peritoneal carcinomatosis (PC). BACKGROUND: The traditional rule is to resect the ovaries systematically when PC is found at surgery. METHODS: A new policy was developed to preserve the ovaries when they were macroscopically normal in young women with PC of different origin who expressed a strong desire for future pregnancy. RESULTS: A total of 106 women younger than age 41 years underwent complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. At least one ovary was preserved in 29 % of them (and in 44 % of those who strongly wished future pregnancy). Among resected "normal" ovaries, 17 % were involved by tumor at the final pathologic examination. Among the resected "suspicious" ovaries, 38 % were involved. Among the 29 preserved ovaries (in 21 women), after a median follow-up of 32 months, 4 (14 %) developed ovarian recurrence, in 3 of them associated with other metastases. Two women became pregnant. In five women with partially normal ovary, egg harvesting and cryopreservation was performed. CONCLUSIONS: This new policy allowed ovarian preservation in 44 % of the young women wishing childbearing and allowed two births. Recurrence in the preserved ovary was 14 % with our criteria of selection. This policy is promising but can be further improved.


Assuntos
Carcinoma/terapia , Neoplasias Colorretais/patologia , Mesotelioma/terapia , Neoplasias Ovarianas/cirurgia , Ovário/cirurgia , Neoplasias Peritoneais/secundário , Neoplasias Peritoneais/terapia , Pseudomixoma Peritoneal/terapia , Adolescente , Adulto , Antineoplásicos/administração & dosagem , Carcinoma/secundário , Feminino , Preservação da Fertilidade , Humanos , Hipertermia Induzida , Infusões Parenterais , Mesotelioma/secundário , Recuperação de Oócitos , Tratamentos com Preservação do Órgão , Neoplasias Ovarianas/secundário , Ovariectomia , Ovário/patologia , Guias de Prática Clínica como Assunto , Gravidez , Taxa de Gravidez , Pseudomixoma Peritoneal/patologia , Adulto Jovem
15.
Arch Gynecol Obstet ; 287(2): 361-7, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22941326

RESUMO

OBJECTIVE AND DESIGN: This was a prospective controlled study to compare the beneficial effects of office microlaparoscopic ovarian drilling (OMLOD) under augmented local anesthesia, as a new modality treatment option, compared to those following ovarian drilling with the conventional traditional 10-mm laparoscope (laparoscopic ovarian drilling, LOD) under general anesthesia. METHODS: The study included 60 anovulatory women with polycystic ovary syndrome (PCOS) who underwent OMLOD (study group) and 60 anovulatory PCOS women, in whom conventional LOD using 10-mm laparoscope under general anesthesia was performed (comparison group). Transvaginal ultrasound scan and blood sampling to measure the serum concentrations of LH, FSH, testosterone and androstenedione were performed before and after the procedure. Intraoperative and postoperative pain scores in candidate women were evaluated during the office microlaparoscopic procedure, in addition to the number of candidates who needed extra analgesia. RESULTS: Women undergoing OMLOD showed good intraoperative and postoperative pain scores. The number of patients discharged within 2 h after the office procedure was significantly higher, without the need for postoperative analgesia in most patients. The LH:FSH ratio, mean serum concentrations of LH and testosterone and free androgen index decreased significantly after both OMLOD and LOD. The mean ovarian volume decreased significantly (P < 0.05) a year after both OMLOD and LOD. There were no significant differences in those results after both procedures. CONCLUSION: Intra- and postoperatively augmented local anesthesia allows outpatient bilateral ovarian drilling by microlaparoscopy without general anesthesia. The high pregnancy rate, the simplicity of the method and the faster discharge time offer a new option for patients with PCOS who are resistant to clomiphene citrate. Moreover, ovarian drilling could be performed simultaneously during the routine diagnostic microlaparoscopy and integrated into the fertility workup of these patients.


Assuntos
Assistência Ambulatorial/métodos , Laparoscopia/métodos , Microcirurgia/métodos , Ovário/cirurgia , Síndrome do Ovário Policístico/cirurgia , Gravidez/estatística & dados numéricos , Adulto , Analgésicos/uso terapêutico , Anestesia Geral , Anestesia Local , Estudos de Viabilidade , Feminino , Seguimentos , Humanos , Pessoa de Meia-Idade , Ovulação , Medição da Dor , Dor Pós-Operatória/tratamento farmacológico , Dor Pós-Operatória/prevenção & controle , Estudos Prospectivos , Resultado do Tratamento
16.
J Bone Miner Metab ; 30(2): 136-43, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21773701

RESUMO

To assess the ability of α-zearalanol (α-ZAL) to prevent bone loss in an ovariectomized (OVX) rat model of osteoporosis, α-ZAL was administered intragastrically to rats. After 35 days, the total body bone mineral density (BMD) was assessed in all rats. All sections were processed for immunohistochemistry and hematoxylin and eosin staining. One-way ANOVA and an LSD multiple-range test were used to determine the significant differences between groups. BMD was lower in the OVX and OVX + α-ZAL high-dose (OVX + High) groups compared to the sham-operated (Sham), OVX + 17ß-ethinylestradiol (OVX + E(2)), OVX + α-ZAL medium-dose (OVX + Medium) and OVX + α-ZAL low-dose (OVX + Low) groups (P < 0.05). Clear bone trabeculae arrangements were observed in the OVX + E(2,) OVX + Medium and OVX + Low groups. The expressions of bone morphogenetic proteins and basic fibroblast growth factor were up-regulated in the OVX + E(2), OVX + Medium and OVX + Low groups compared to the OVX and OVX + High groups (P < 0.05). The OVX + E(2), OVX + Medium and OVX + Low groups showed lower levels of bone Gla protein, bone alkaline phosphatase, tartrate-resistant acid phosphatase and tumor necrosis factor α expressions than the OVX and OVX + High groups (P < 0.05). The administration of α-ZAL to ovariectomized rats reverses bone loss and prevents osteoporosis.


Assuntos
Reabsorção Óssea/tratamento farmacológico , Estrogênios/deficiência , Ovário/metabolismo , Progesterona/deficiência , Zeranol/uso terapêutico , Fosfatase Ácida/metabolismo , Fosfatase Alcalina/metabolismo , Animais , Peso Corporal/efeitos dos fármacos , Densidade Óssea/efeitos dos fármacos , Proteínas Morfogenéticas Ósseas/metabolismo , Reabsorção Óssea/enzimologia , Reabsorção Óssea/patologia , Feminino , Fator 2 de Crescimento de Fibroblastos/metabolismo , Isoenzimas/metabolismo , Osteocalcina/metabolismo , Ovariectomia , Ovário/efeitos dos fármacos , Ovário/cirurgia , Ratos , Ratos Sprague-Dawley , Coloração e Rotulagem , Fosfatase Ácida Resistente a Tartarato , Tíbia/efeitos dos fármacos , Tíbia/enzimologia , Tíbia/patologia , Fator de Necrose Tumoral alfa/metabolismo , Zeranol/farmacologia
17.
Menopause ; 18(9): 1010-7, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21505371

RESUMO

OBJECTIVE: Adenosine monophosphate (AMP)-activated protein kinase (AMPK) plays an important role in regulating whole-body energy homeostasis. The aim of this study was to investigate dietary α-lipoic acid (α-LA) supplementation on the activation of AMPK in both central and peripheral tissues in obese rats induced by ovariectomy. METHODS: Ovariectomized (Ovx) rats were treated with α-LA (200 mg/kg) 3 to 10 weeks after surgery. Body weight, food intake, fat mass, phosphorylated AMPKα (pAMPKα), and phosphorylated acetyl-CoA carboxylase (ACC) protein expression in both the hypothalamus and white adipose tissue (WAT) as well as plasma leptin and adiponectin levels were measured in rats after either Ovx or sham operations. RESULTS: Compared with control rats, ovariectomy led to increased body weight, food intake, and WAT mass 2 to 10 weeks after surgery. Furthermore, plasma leptin and adiponectin levels as well as hypothalamic pAMPKα expression were significantly increased after ovariectomy, accompanied by a reduction in pAMPKα expression in WAT after ovariectomy. However, after treatment with α-LA, the elevation of leptin and adiponectin levels and the activation of hypothalamic AMPKα and ACC, as induced by ovariectomy, were significantly suppressed. Meanwhile, decreased fat mass and increased pAMPKα and phosphorylated ACC expression in the WAT were observed in Ovx rats treated with α-LA. CONCLUSIONS: α-LA significantly decreased appetite and fat accumulation, possibly through the regulation of central and peripheral AMPK activities in rats. Therefore, this study provides a rationale for the therapeutic use of α-LA for obesity in postmenopausal women.


Assuntos
Proteínas Quinases Dependentes de AMP Cíclico/metabolismo , Obesidade/metabolismo , Ovário/metabolismo , Ácido Tióctico/farmacologia , Complexo Vitamínico B/farmacologia , Acetil-CoA Carboxilase/metabolismo , Adiponectina/sangue , Tecido Adiposo/efeitos dos fármacos , Tecido Adiposo/metabolismo , Animais , Peso Corporal/efeitos dos fármacos , Ingestão de Alimentos/efeitos dos fármacos , Feminino , Hipotálamo/efeitos dos fármacos , Hipotálamo/metabolismo , Leptina/sangue , Ovariectomia , Ovário/cirurgia , Ratos , Ratos Sprague-Dawley , Ácido Tióctico/metabolismo , Complexo Vitamínico B/metabolismo
18.
J Gynecol Obstet Biol Reprod (Paris) ; 39(8 Suppl): F71-8, 2010 Dec.
Artigo em Francês | MEDLINE | ID: mdl-21074336

RESUMO

The discovery of breast cancer carcinoma sensitivity to estradiol (E) suppression is the starting point of hormonal treatment. Hormonal receptors (ER and PR) are the pathway of the action of estradiol on breast tumor cells. The detection of at least one of these two receptors is needed to classify a tumor as hormone sensitive. The hormonal treatment of breast cancer attempts to suppress the stimulating action of E on tumor cells. This can be done by decreasing E synthesis--ovarian suppression (OS) or aromatase inhibitors (AIs)--or by compelling with E on receptors--tamoxifen (TAM). In advanced breast cancer, hormonal treatment gives good response with few side effects. In young patient, the treatment is based on TAM. It could be associated with OS. In post-menopausal women, AIs are more potent than TAM. They are used in the first line treatment and TAM as a second line. Fulvestrant is not superior TAM or AIs. In the adjuvant setting, hormonal treatment gives a significant reduction of recurrence and death. In young patient, the treatment is based on TAM. It could be associated with OS. In post-menopausal patients, adjuvant treatment must include an AIs for at least one part of the treatment. A survey of bone density is necessary.


Assuntos
Antineoplásicos Hormonais/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Fatores Etários , Inibidores da Aromatase/uso terapêutico , Densidade Óssea , Neoplasias da Mama/química , Neoplasias da Mama/terapia , Quimioterapia Adjuvante , Antagonistas de Estrogênios/uso terapêutico , Feminino , Hormônio Liberador de Gonadotropina/análogos & derivados , Humanos , Ovário/efeitos dos fármacos , Ovário/efeitos da radiação , Ovário/cirurgia , Pós-Menopausa , Receptores de Estrogênio/análise , Receptores de Progesterona/análise , Tamoxifeno/uso terapêutico
19.
Reprod Biomed Online ; 20(3): 403-9, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20089454

RESUMO

The aim of this randomized double-blind placebo-controlled pilot study was to evaluate N-acetyl-cysteine (NAC) as an adjunctive therapy following unilateral laparoscopic ovarian drilling (LOD) for clomiphene citrate-resistant women with polycystic ovary syndrome (PCOS). A total of 60 patients with clomiphene citrate-resistant PCOS who underwent unilateral LOD were assigned randomly to receive either NAC 1.2 g/d (group A=30) or placebo (group B=30) for 5 days starting at day 3 of the cycle for 12 consecutive cycles. The primary outcome was pregnancy rate; secondary outcomes were ovulation rates, endometrial thickness and pregnancy outcome. Baseline clinical, endocrine, and sonographic characteristics were similar in the two groups. A significant increase in both ovulation and pregnancy rates was observed in the NAC group, compared with placebo [87% versus 67% (RR 1.3; 95% CI 1.2-2.7) and 77% versus 57% (RR 1.4; 95% CI 1.1-2.7), respectively, P<0.01]. Moreover, miscarriage rates were significantly lower and live birth rates were significantly higher in the NAC group [8.7% versus 23.5% (RR 0.4; 95% CI 0.1-3.7) and 67% versus 40% (RR 1.7; 95% CI 0.3-3.5), respectively, P<0.01]. In conclusion, NAC is a novel adjuvant therapy after unilateral LOD which might help improve overall reproductive outcome.


Assuntos
Acetilcisteína/uso terapêutico , Fármacos para a Fertilidade Feminina/uso terapêutico , Ovário/cirurgia , Síndrome do Ovário Policístico/tratamento farmacológico , Adolescente , Adulto , Clomifeno/uso terapêutico , Resistência a Medicamentos , Feminino , Humanos , Laparoscopia , Ovulação/efeitos dos fármacos , Indução da Ovulação/métodos , Projetos Piloto , Placebos , Gravidez , Taxa de Gravidez
20.
J Pediatr Surg ; 43(7): 1380-4, 2008 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-18639702

RESUMO

A girl with asynchronous, bilateral ovarian torsion with previous oophorectomy presented with her second torsion. A laparoscopic untwisting of the torsed ovary was performed, treatment with hyperbaric oxygen therapy was given, and the outcome was followed with contrast-enhanced ultrasound. After 1 month, a laparoscopic oophoropexy was performed. The detorsed ovary regained its circulation and decreased in size. It looked normal at the time for oophopexy and at follow-up. This case supports the evidence of an ovarian-sparing approach to ovarian torsion in children and supports oophoropexy after torsion of a detorsed, otherwise normal ovary in the premenarcheal girl.


Assuntos
Oxigenoterapia Hiperbárica , Doenças Ovarianas/cirurgia , Ovário/cirurgia , Anormalidade Torcional/cirurgia , Criança , Meios de Contraste , Feminino , Humanos , Laparoscopia , Doenças Ovarianas/diagnóstico por imagem , Anormalidade Torcional/diagnóstico por imagem , Ultrassonografia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA